HOME › DRUGS › BELZUTIFAN
ACTIVE SUBSTANCE / INN

BELZUTIFAN

Brand name(s): Welireg, WELIREG
FDA LISTED
EMA LISTED
PRESCRIPTION
AUTHORISED
NDA215383
Carcinoma, Renal Cell;von Hippel-Lindau Disease
ACTIVE SUBSTANCE
Belzutifan
REGULATORS
FDA · EMA
SPONSORS / MAH
Merck Sharp & Dohme B.V., MERCK SHARP DOHME
TOTAL APPLICATIONS
2
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
WELIREGNDA215383MERCK SHARP DOHMEPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
WeliregMerck Sharp & Dohme B.V.Authorised12/02/2025Carcinoma, Renal Cell;von Hippel-Lindau Disease

FULL INTELLIGENCE ON BELZUTIFAN

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →